Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

1.180 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.180
Bid (Size) 1.170 (1)
Ask (Size) 1.250 (2)
Prev. Close 1.180
Today's Range 1.180 - 1.180
52wk Range 0.6181 - 2.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins
Via Investor Brand Network
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
From FSD Pharma Inc.
Via Business Wire

Performance

YTD
+52.85%
+52.85%
1 Month
-3.28%
-3.28%
3 Month
-18.06%
-18.06%
6 Month
+45.48%
+45.48%
1 Year
+15.69%
+15.69%

More News

Read More
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video
Via Investor Brand Network
Exposures Product Safety
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction
Via Investor Brand Network
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari
Via Investor Brand Network
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
From FSD Pharma Inc.
Via Business Wire
Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial
Via Investor Brand Network
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
From FSD Pharma Inc.
Via Business Wire
Sidoti's Micro-Cap Virtual May Conference
Via ACCESSWIRE
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference
Via Investor Brand Network
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
From FSD Pharma Inc.
Via Business Wire
Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation
Via Benzinga
GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation
Via News Direct
Topics Lawsuit
Exposures Financial Legal
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
Dynamic Duo of Celsius Holdings Fame join FSD Pharma calling Medical Product under Development “Unique and Disruptive”
Via AB Newswire
Topics Bankruptcy
Exposures Financial Legal
North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
Via FinancialNewsMedia
GBB Drink Lab Sends a Cease-and-Desist Demand
Via News Direct
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline
Via Investor Brand Network
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
From FSD Pharma Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.